Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 14/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325828 | 0.82 | PIK3CD (0.42) | PIK3CDPIK3CANAMPTTDO2PTGDR2 | |
| SCHEMBL4316571 | 0.74 | PIK3CD (0.43) | PIK3CDPIK3CANAMPTTDO2EGFR | |
| SCHEMBL4316563 | 0.74 | PIK3CD (0.43) | PIK3CDPIK3CANAMPTTDO2EGFR | |
| SCHEMBL4325902 | 0.73 | PIK3CD (0.41) | PIK3CDPIK3CAGPR52NAMPTTDO2 | |
| SCHEMBL4331608 | 0.72 | PIK3CD (0.40) | PIK3CDPIK3CAGPR52NAMPTTDO2 | |
| SCHEMBL4341809 | 0.69 | SMN1; SMN2 (0.45) | PIK3CDPIK3CANAMPTTDO2 | |
| SCHEMBL27893740 | 0.68 | PIK3CD (0.54) | PIK3CDPIK3CATDO2EGFR | |
| SCHEMBL20687402 | 0.67 | PIK3CD (0.73) | PIK3CDPIK3CATDO2EGFR | |
| SCHEMBL4341802 | 0.67 | FYN (0.39) | PIK3CDPIK3CANAMPTEGFR | |
| SCHEMBL4312104 | 0.66 | EPHX1 (0.54) | PIK3CDPIK3CANAMPTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | PIK3CD 1880/4885PIK3CA 2244/4885GPR52 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.